Accretion Pharmaceuticals Limited
Accretion Pharmaceuticals Limited, established in 2012, produces and sells tablets, capsules, and healthcare products, offering both generic and branded formulations. It provides contract manufacturing services for domestic and international clients, including government and private institutions.
What Accretion files
- Others33
- Investor Meet12
- Updates8
- Important3
- PPTs2
- Board Meeting2
The company's board approved expanding its business scope in pharmaceuticals and healthcare. It also seeks to increase borrowing limits and enhance flexibility for loans, guarantees, and investments. These strategic moves, aimed at future growth, require shareholder approval via postal ballot.
Accretion Pharma notified shareholders about the 3rd Annual General Meeting and access to the FY25-26 Annual Report via a weblink, especially for those without registered emails.
Accretion Pharma reported strong FY26 financials: Revenue up 56.21% to 89.63 Cr, PAT up 42.30% to 9.67 Cr. H2 FY26 revenue grew 18.24% to 45.89 Cr. Growth was driven by volume, product mix, and export expansion into Africa, LatAm, and Southeast Asia. Margins were impacted by input costs and strategic...
Accretion Pharmaceuticals was honored with the "ZEE 24 TAAS HEALTHCARE CONCLAVE" award, presented by Mr. Prakashrao Abitkar from the Ministry of Public Health and Family Welfare, Government of Maharashtra.
Accretion Pharma's H1 FY26 saw revenue surge 135.59% to ₹43.74 Cr, EBITDA 62.94% to ₹7.07 Cr, and PAT 92.81% to ₹4.75 Cr. Growth fueled by IPO-backed capacity expansion and diversified product offerings. Expanded global reach with new market approvals for African exports.